ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
|
ORIGINAL RESEARCH ARTICLES |
Liver Function Tests During Of Tuberculosis Treatment
Kürşat Uzun*, Bülent Özbay*, Abdullah Gülsün*, İsmail Zehİr*
* Dr.,Yüzüncü Yıl Üniversitesi Tıp Fakültesi Göğüs Hastalıkları ve Tüberküloz AD, VAN
Hepatotoxicity is the most important side effect of antituberculosis drugs. However temporary elevations of transaminase levels are usually seen in the first month of the treatment. In this study course of transaminase levels and hepatotoxicity were evaluated in 58 patients (35 males, 23 females, mean age 32,3±15,6) with tuberculosis (41 pulmonary tb, 13 pleural tb, 4 lymphadenit tb). Treatment was stopped temporarily due to hepatotoxicity symptoms such as nausae, vomiting and transaminase elevation in four patients and these patients were excluded from the study.
Alanine aminotransfarese(ALT), aspartate aminotransaminase(AST), total and direct bilirubin values were measured before and 1, 3, 7, 15, and 30 days after treatment. All patients had normal transaminase levels before the treatment. Mean transaminase value reached to maximum level at seventh day and returned to baseline at the 30 th day of the treatment. Twenty five patients(46,3%) had asymptomatic transaminase elevations. Transaminase index(TI) was calculated as the ratio of maximum transaminase value of treatment period over pretreatment value. Transaminase index(TI) was ³5 in six patients, two of these patients TI was ³10. None of these patients with transaminase elevations had symptoms of hepatotoxicity and elevated bilirubin levels.
In ten patients with transaminase elevation, ALT and AST values were about 3-5 fold of normal up levels. Treatment was not stopped ın these patients, but transaminase levels were followed. All of the patients had normal transaminase levels at 30 th day of the treatment.
In conclusion, for patients receiving antituberculosis drugs, in the case of transaminase elevations without hepatotoxicity symptoms, with negative hepatitis markers, treatment need not be discontinued, patients must be followed up and cessation of therapy must be determined according to following transaminase values and hepatotoxicity symptoms.Keywords: Liver function tests,
Antituberculosis drugsTurkiye Klinikleri J Med Sci 1999, 19:137-140
|
|
|
|
|
